Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data On March 24, Guggenheim Partners raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $36 from $35. It reiterated a Buy rating on the shares. The analyst pointed to upcoming data from the MEVPRO-1 Phase 3 trial of mevrometostat in second-line and later mCRPC, expected in the second half of 2026. Based on that setup, the firm sees about $2 per share upside if the trial succeeds, compared with roughly $1 downside if it does not. On March 23, Reuters reported that Pfizer and Valneva said their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even though it missed its main goal. Pfizer said the overall results still support confidence in the vaccine and confirmed plans to move forward with regulatory submissions. The vaccine showed 73.2% efficacy starting 28 days after the fourth dose in reducing confirmed Lyme disease cases compared to placebo. The companies explained that
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better” [Yahoo! Finance]Yahoo! Finance
- Consecutive approvals of Opdivo for Hodgkin's lymphoma to boost sales growth [Yahoo! Finance]Yahoo! Finance
- ????????????? - ??????????????????2026-2035? [CNET News]CNET News
- Income Investors Face a Hard Truth About Pfizer's Payout Safety [Yahoo! Finance]Yahoo! Finance
- Is Pfizer Stock a Buy After This Win? [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/16/26 - Form 4
- 3/12/26 - Form ARS
- PFE's page on the SEC website